DOCSLIB.ORG

Accounts and Data Accounts and Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Accounts and Data Accounts and Data Accounts and Data Accounts and Data Statements 4 Risk factors 7 Accounting policies 8 The Novozymes Group 16 Summary and key figures 2003-1999 37 Companies in the Novozymes Group 38 Data for Environmental and Social Responsibility and Knowledge 39 Share information 43 Board of Directors and Executive Management 46 The Annual Accounts of the Parent Company Novozymes A/S are to be found on the enclosed CD-ROM. We imagine a future where our bio- logical solutions create the necessary balance between better business, “ cleaner environment and better lives. ” The Novozymes Group Statements Statement of the Board of Directors and the Management The Board of Directors and the Management have considered and approved the Annual Report for 2003 of Novozymes A/S. The Annual Report has been prepared in accordance with the Danish Company Accounts Act, the current Danish accounting standards, Danish accounting standard no. 21 “Leases”, Danish accounting standard no. 22, “Revenue”, and the regulations of the Copenhagen Stock Exchange for the presentation of accounts by listed companies. In our opinion the accounting policies used are appropriate and the Annual Report gives a true and fair view of the Group’s and the Parent Company’s* assets, liabilities, financial position and net profit, and the Group’s cash flows. The Annual Report is submitted for the approval of the Annual Meeting of Shareholders. Gladsaxe, January 29, 2004 Management: Steen Riisgaard Per Falholt Per Månsson Peder Holk Nielsen Arne W. Schmidt President and CEO Board of Directors: Henrik Gürtler Kurt Anker Nielsen Paul Petter Aas Jerker Hartwall Arne Hansen Chairman Vice chairman Lars Bo Køppler Ulla Morin Walther Thygesen Hans Werdelin * The Annual Accounts of the Parent Company Novozymes A/S are only included on the CD-ROM enclosed with the Annual Report. The Annual Accounts of the Parent Company form an integral part of the Annual Report. 4 5 Auditors’ report We have audited the Annual Report of Novozymes A/S for 2003*. The Annual Report is the responsibility of the Company’s Board of Directors and Management. Our responsibility is to express an opinion on the Annual Report based on our audit. Basis of opinion We conducted our audit in accordance with International and Danish auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance that the Annual Report is free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the Annual Report. An audit also includes assessing the accounting policies used and significant estimates made by the Board of Directors and Management, as well as evaluating the overall Annual Report presentation. We believe that our audit provides a reasonable basis for our opinion. Our audit did not give rise to any qualifications. Opinion In our opinion, the Annual Report gives a true and fair view of the Group’s and the Parent Company’s** assets, liabil- ities, shareholders’ equity and financial position at December 31, 2003, and of the results of the Group’s and the Parent Company’s operations and consolidated cash flows for 2003 in accordance with the Danish Company Accounts Act and the accounting regulations for the companies listed on the Copenhagen Stock Exchange. Gladsaxe, January 29, 2004 PricewaterhouseCoopers Ernst & Young Statsautoriseret Revisionsinteressentskab Statsautoriseret Revisionsaktieselskab Morten Iversen Lars Holtug Ole Neerup State-Authorised Public Accountant State-Authorised Public Accountant State-Authorised Public Accountant * In addition to the statutory audit of the Annual Report comprising pages 1-43 (Report) and 1-47 (Accounts and Data), PriceWaterhouseCoopers has performed a separate review and assessment of qualitative and quantitative aspects of Environmental and Social Responsibility in the Annual Report, and provided the separate statement thereon published on page 6 (Accounts and Data). ** The Annual Accounts of the Parent Company Novozymes A/S are only included on the CD-ROM enclosed with the Annual Report. The Annual Accounts of the Parent Company form an integral part of the Annual Report. 4 5 The Novozymes Group Statements Statement from PricewaterhouseCoopers on Environmental and Social Responsibility comprised by the Annual Report of Novozymes for 2003 As independent auditors, we have, in addition to our audit of the Annual Report and at the request of the Manage- ment, reviewed and assessed the description of Environmental and Social Responsibility in the Annual Report. The quantitative and qualitative aspects on which this statement is based are also comprised by our audit of the Annual Report. Moreover, we have reviewed and assessed management systems, processes and competences supporting Novozymes’ performance in these areas. Company Management is responsible for the Annual Report. It is our responsibility, on the basis of the AA1000 Assurance Standard, to conclude whether Novozymes complies with the overall principles hereof. Basis of Conclusion We have performed our work in accordance with ISA 100 Assurance Engagements and the AA1000 Assurance Standard with a view to obtaining reasonable assurance that the Annual Report provides a reliable, accurate and balanced representation as regards Novozymes’ work with respect to Environmental and Social Responsibility. On the basis of an assessment of materiality and risk, our work has comprised a review of management and reporting systems as well as internal control systems, interviews with members of the Executive Management, the Sustainability Development Strategy Group, as well as Management representatives and employees at selected reporting units (Tianjin, China; Franklinton, USA; Kalundborg and Bagsværd, Denmark). Moreover, we have analysed and tested documentation relating to representations made. We have on a test basis reviewed data and underlying documentation and checked whether data has been reported in accordance with the accounting policies applied. Finally, we have assessed the overall presentation. In our opinion, the work performed provides a reasonable basis for our conclusion. Conclusion, Improvements and Recommendations We hereby state that: • in our opinion, Novozymes has identified material stakeholders as well as environmental and social aspects relating to the Company’s activities. In our assessment, proposals and wishes put forward by important stakeholders are heard; • the Annual Report provides the most important, known information concerning Environmental and Social Respon- sibility, and the information provides a reliable, accurate and balanced representation of Novozymes’ work with the activities stated in the section ”Accounting policies”; • this Report will be made available to all Novozymes’ stakeholders; • the existing management and reporting systems as well as the internal control systems support the reliability of the information in the Annual Report. Our recommendations in our Statement in the Annual Report for 2002 have been addressed by Novozymes as follows: • Novozymes identifies stakeholders systematically and efficiently. The identification process takes place at the business units, which report on key stakeholders and aspects to Stakeholder Communications and the Sustainability Development Strategy Group, who coordinate the dialogue. • During 2003, Novozymes further integrated Environmental and Social Responsibility work into the business by establishing the Sustainability Development Strategy Group. The Group reports directly to the Executive Management and consists of, among others, managements of the business units and of the companies in China, USA and Brazil. We recommend that Novozymes: • explain, to an increased extent, how embedding of Environmental and Social Responsibility into the business creates value; • assess the possibility of using a set of indicators showing the extent to which procedures and measures communi- cated are implemented and observed; • conclude the examination as to whether Novozymes may, to an increased extent, achieve benchmarking against other enterprises. Gladsaxe, January 29, 2004 PricewaterhouseCoopers AG, Switzerland PricewaterhouseCoopers, Statsautoriseret Revisionsinteressentskab Thomas Scheiwiller, Dr. Sc.nat. Helle Bank Jørgensen, State-Authorised Public Accountant 6 7 The Novozymes Group Risk factors Risk factors Financial risk factors in the average interest rate on Novozymes’ net interest- Novozymes’ international operations mean that its bearing liabilities would have an effect on profit before profit and loss account and balance sheet are exposed tax of DKK 3.5 million. 36% of the loan portfolio at to a number of financial risk factors. Financial risks are year-end 2003 was at fixed rates of interest. According managed centrally by the Group finance function. The to Novozymes’ treasury policy, free funds may only be use of financial instruments is governed by the treasury invested in government bonds, extremely liquid domestic policy approved by Novozymes’ Board of Directors. This mortgage-credit bonds and money-market deposits. policy contains rules on the financial instruments that can be used for hedging, the counterparties that can be Credit risk used and the risk profile that is to be applied. Financial The Group does not have a significant concentration of instruments are used to hedge existing assets and credit risk. Credit risk is managed by dealing in financial liabilities or expected future net cash flow. instruments and placing deposits
Load more

Recommended publications
  • Conte Annual Report 2000 / 2001
    Coloplast’s Mission Contents Throughout the world we wish to be perceived as depend- Coloplast in brief 2 able providers of consumable products and services. 5 years’ key figures and ratios 3 Our customers are health care professionals and users. Our primary concern is to improve the quality of life of Board and Group Management 4 individuals suffering from a disabling condition. Management report 5 We respond quickly to market needs to ensure the highest level of customer satisfaction. We strive to offer Financial review 11 preferred product ranges based on innovation, advanced technology and cost-effectiveness. Risk factors 15 Accounting policies 17 All employees must be recognised for their empathy with user needs and dependability in business relations. Profit and loss account 19 It is our ambition to attract and retain the best human Balance sheet 20 resources. Consolidated cash flow statement 22 As individuals and as an organisation we will act respon- Auditors’ report and approvals 23 sibly and be socially and environmentally conscious. Notes 24 We strive to be the best within our businesses, thereby achieving growth and value for the company, the em ploy- ees and shareholders. Stakeholder reporting Annual Report 2000 / 2001 – value creation and knowledge management 32 Customers 33 Employees 38 Society 41 Shareholders 43 Indicators for value drivers and value propositions 48 Artist of the year 50 Group addresses Executives Coloplast Mission Coloplast A/S Coloplast, Conveen, Comfeel, Holtedam 1 Amoena, Sween, Compeed, DK-3050 Humlebæk Assura, Easiflex, EasiCath, Coloplast’s Annual Report for 2000/01 has its own Tel. + 45 49 11 11 11 SpeediCath, Biatain, Contreet, microsite on our corporate website at the address: Fax + 45 49 11 15 55 and Prema are registered trade- E-mail: [email protected] marks of the Coloplast Group.
    [Show full text]
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold Udfordrende markeder dæmper salgsvæksten Uændret Hold-anbefaling siden 20/04/2016 Vi fastholder vores Hold-anbefaling på Novozymes Dagens regnskab er lidt svagere, end vi havde ventet. Hård priskonkurrence i ’Bioenergi’ og økonomisk Analysedato: 10/08/2016 pressede kunder i ’Landbrug og Foder’ dæmper Novozymes’ salgsvækst. Pris- fastsættelsen af Novozymes-aktien afspejler efter vores vurdering Novozymes’ Aktuel kurs kl. 12:11: kortsigtede forretningsmuligheder. 295,00 DKK Salgsvæksten skuffer i årets 2. kvartal Omsætningen på 3.429 mio. kr. i 2. kvartal 2016 er 3,3% dårligere end vores estimat (-3,5% i Begivenhed: forhold til markedsforventningen). Resultatet af primær drift på 961 mio. kr. i 2. kvartal 2016 er 2,9% under vores estimat (-2,6% i forhold til markedsforventningen). I forhold til vores for- 2. kvartalsregnskab ventning er det specielt salget i divisionerne ’Bioenergi’ og ’Landbrug og Foder’, der viser en svagere end ventet udvikling i 2. kvartal. Novozymes justerer salgsprognosen for 2016 i lokal Seneste analyse: valuta. Selskabet venter nu en salgsvækst i lokal valuta på 2-4% i 2016 mod tidligere 3-5%. 05/08/16 – Vækst i ’Vaskemid- Novozymes forventer, at salgsvæksten i danske kroner forbliver uændret på 1-3% i 2016. ler’ – Tilbagegang i ’Bioenergi’ Salgsvæksten i ’Vaskemidler’ overgår vores forventning Den organiske salgsvækst i divisionen ’Vaskemidler’ på 4% i 2. kvartal er lidt bedre end vo- res estimat på 3%. Vi hæfter hos ved, at salget vokser i Asien drevet af øget penetration af Kalender: enzymer i flydende vaskemidler. Yderligere noterer vi os, at den positive salgsudvikling er 26/10/16 – 3.
    [Show full text]
  • Novo Nordisk Annual Report 2012
    novo nordisk annual report 2012 Diabetes – an emergency in slow motion Strategy Sustainable growth is all about – can it be done? choice Insulin in Novo Nordisk’s performance in 2012 is a result of important decisions made in recent years a tablet – but there is more to the story – why is it so difficult? Contents Accomplishments and results 2012 1 Letter from the Chairman 2 Letter from the CEO 4 Performance highlights 6 2012 performance and 2013 outlook Our business 15 Strategy is all about choice 20 Diabetes – an emergency Diabetes – an emergency in slow motion 20 in slow motion 22 The protein powerhouse 24 Insulin treatment is a balancing act 26 Insulin in a tablet – why is it so difficult? 28 Simple injections 29 Prevent bleedings 30 Pipeline overview 32 Many markets – one model 38 Sustainable growth – can it be done? 41 With every big opportunity comes a risk Governance, leadership and shares 44 Shares and capital structure The protein 46 Corporate governance 22 powerhouse 49 Remuneration 52 Board of Directors 54 Executive Management Financial, social and environmental statements 55 Consolidated financial, social and environmental statements 104 Financial statements of the parent company 109 Management’s statement and Auditor’s reports Additional information 112 More information Simple 28 injections 113 Product overview The Management review, as defined by the Danish Financial Statements Act (FSA), is found on pp 1–54 and 94. This Annual Report is published in both a Danish and an English language version. In the event of any discrepancies, the Danish version shall prevail. 1 Chairman of the Board of Directors Sten Scheibye at the Annual General Meeting in March 2012.
    [Show full text]
  • Aktiekommentar Novozymes
    Aktiekommentar Novozymes Sælg Novozymes står på dørtærsklen til et kommercielt Uændret gennembrud i 2G-biobrændstofindustrien Aktuel kurs: 216,30 DKK Begivenhed: Vi fastholder Sælg-anbefalingen på Novozymes. Værdiansættelsen af Novozy- mes-aktien indregner efter vores vurdering allerede store forventninger til Novo- zymes’ fremtidige salg og indtjening fra 2G-biobrændstofenzymer. 2G-industrien Optakt til kapitalmar- er dog i sin spæde opstartsfase. Der er fortsat stor usikkerhed forbundet med kedsdag hvilke teknologiske løsninger, der vil blive markedsledende. Vi forventer dog, at Novozymes vil få en betydelig markedsposition som leverandør til 2G-industrien. Baggrund: Novozymes afholder kapitalmarkedsdag den 31. oktober 2013. Det overordnende tema for dagen er anden generations biobrændstof (2G) og mulighederne for Novozymes i denne indu- stri. Verdens første kommercielle 2G-bioethanolproduktion er for nylig startet op i Cresentino i Italien med Novozymes som enzymleverandør. Produktionsanlægget er opført af italienske Beta Renewables, som Novozymes ejer 10% af. Konklusion: På kapitalmarkedsdagen vil vi have fokus på følgende punkter: - Produktionsøkonomien på det italienske 2G-anlæg – er det kommercielt konkurren- cedygtigt? - Statusopdatering på Novozymes’ globale partnerskabsaftaler – tidshorisont for kom- merciel 2G-produktion på forskellige markeder - Novozymes/Beta Renewables styrker i forhold til konkurrerende teknologier Vi forventer, at Novozymes i 2015 kan opnå et globalt enzymsalg til 2G- biobrændstofsproduktion på 213 mio. kr. stigende til 2.166 mio. kr. i 2020. Vi forventer, at Ki- na og Brasilien vil agere vækstmotor for udviklingen af 2G-industrien, mens vi først forventer, at udviklingen i USA kommer op i tempo efter 2015. Det er efter vores vurdering helt centralt, at Novozymes har indgået et samarbejde med itali- enske Beta Renewables.
    [Show full text]
  • Novozymes Continues to Deliver on the Global Goals
    Novozymes continues to deliver on the Global Goals At the UN General Assembly in New York in September 2015, Novozymes joined the rest of the world in welcoming the UN Sustainable Development Goals (SDGs) and the 2030 Agenda for sustainable development. This agenda puts the world on a path toward a more sustainable, viable, low-carbon future, with the SDGs providing a partnership platform for governments, civil society and business to help tackle the world’s challenges. As a global market leader in biological solutions, producing a wide range of industrial enzymes and microorganisms, the intrinsically sustainable nature of Novozymes’ solutions enables us to contribute to one or more of the Sustainable Development Goals (SDGs), directly or indirectly. Every day, we strive to do our part to deliver on the SDGs, from the core of our business and right through our operations. Our contributions are outlined below. In addition, read ‘Working with the SDGs’ in ‘The Novozymes Report 2020’. Embracing our responsibility To shape a future of better business for us, our customers and the world, we need to have a sound, balanced and growing business. This will allow us to continue investing in our leadership position within biotechnology and capture new opportunities in the industries we serve. Our strategy Better business with biology is inspired by the societal needs defined by the Global Goals. Through the strategy, we are committed to developing solutions that can contribute to solving three global challenges: Climate, Water and Production and Consumption. We are also committed to operating our business responsibly and investing to minimize our negative environmental footprint.
    [Show full text]
  • Invitation Annual Shareholders' Meeting 2015
    INVITATION ANNUAL SHAREHOLDERS’ MEETING 2015 To the shareholders of Novozymes A/S The Board of Directors is pleased to invite you to the Company’s Annual Shareholders’ Meeting on WEDNESDAY FEBRUARY 25, 2015 AT 4:00 P.M. at Ballerup Super Arena, Ballerup Idrætsby 4, 2750 Ballerup, Denmark AGENDA: 1. Report on the Company’s activities 5. Election of Chairman The Board of Directors proposes re-election of the 2. Presentation and approval of the audited incumbent Chairman. annual report Henrik Gürtler 3. Resolution on distribution of profit in Born 1953, Chairman, MSc accordance with the approved annual (Engineering), chemical engi- report neer. The Board of Directors re- The Board of Directors proposes a dividend of DKK commends re-election of 3.00 per A/B share of DKK 2 Henrik Gürtler because of his in-depth knowledge of Novozymes’ business, and expertise in managing and 4. Approval of remuneration to members of working in an international biotechnology company. the Board of the Directors for the present Henrik Gürtler serves as chairman of the board of Det year Alm. Danske Ejendomsselskab A/S (DADES A/S). Henrik Gürtler has been a member of the Board of The Board of Directors proposes that the fees for the Directors since 2000. board members and the Audit Committee shall be fixed to: 6. Election of Vice Chairman • The base fee for board members shall be DKK The Board of Directors proposes re-election of the 500,000 incumbent Vice Chairman. • The Chairman of the Board of Directors shall receive 3.0 times the base fee Agnete Raaschou-Nielsen • The Vice Chairman of the Board of Directors shall Born 1957, Chairman of receive 2.0 times the base fee Brdr.
    [Show full text]
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold To cylindre i salgsvækstmotoren sætter ud Uændret Vi fastholder Hold-anbefalingen på Novozymes. Dagens regnskab byder på en Aktuel kurs: overraskende nedjustering af den organiske salgsvækst drevet af udfordringer inden for vaskemidler og bioenergi. Vi forventer ikke, at Novozymes vil være i 321,1 DKK stand til at løse udfordringerne på den korte bane. Begivenhed: Salgsvæksten skuffer markant i 2. kvartal Omsætningen på 3.449 mio. kr. i 2. kvartal 2015 er 5,2 % dårligere end vores estimat (-6,1% 2. kvartalsregnskab ift. markedsforventningerne). Resultatet af primær drift på 930 mio. kr. i 2. kvartal 2015 er 4,7% dårligere, end vi havde forventet (-6,3% ift. markedsforventningerne). Det skal dog bemærkes, at driftsresultatet i 2. kvartal er negativt påvirket af en nedskrivning på 50 mio. kr. Seneste analyse: relateret til Novozymes’ farmaceutiske forretning. Når der ses bort fra nedskrivningen er 17/04/15 – Aktieudsyn – Min- overskudsgraden i 2. kvartal på 28,4%, hvilket er markant over vores estimat på 26,8%. No- dre valuta-drevet nedjustering vozymes nedjusterer salgsprognosen for 2015. Novozymes forventer nu, at salget vil vokse på vej 13-16% i danske kroner i 2015 mod tidligere 16-18%. I lokal valuta forventer Novozymes, at salget vil vokse med 4-7% mod tidligere 7-9%. Den stærke udvikling i indtjeningen i årets første seks måneder betyder, at Novozymes fastholder indtjeningsprognosen for 2015 på trods af den svagere salgsudvikling. Kalender: 22/10/15 – 3. kvartalsregnskab Hård konkurrence bland nordamerikanske vaskemiddelproducenter skaber udfordringer 19/01/16 – Årsregnskab 2015 Omsætningen fra vaskemiddelenzymer er 2% under vores estimat.
    [Show full text]
  • Factsheet | 27 September, 2021 LU0012195615 Marketing Material
    Danske Invest SICAV Denmark Focus Class A Factsheet | 27 September, 2021 LU0012195615 Marketing material Objectives and investment policy Manager Objectives Name: The objective of this fund is to achieve above-market performance. The share Jesper Neergaard Poll class is accumulating. Danske Bank Asset Management Title: Investment policy Chief Portfolio Manager The fund invests mainly in a narrow and focused selection of Danish equities. Background: The fund promotes various environmental and social characteristics and good M.Sc. governance practices through a commitment to systematically identify and Years of experience: address sustainability factors throughout the investment management processes 28 and through active ownership. In actively managing the fund’s portfolio, the management team selects securities that appear to offer superior investment characteristics. 10 largest holdings as of 30.07.2021 *) The fund generally expects that its holdings, and therefore its performance, may not differ significantly from those of the benchmark. Name of investment/security Weight The fund may use derivatives for hedging and efficient portfolio management. Novo Nordisk B 9.9% Recommendation: This fund may not be appropriate for investors who plan to Dsv 8.1% withdraw their money within 5 years. Carlsberg B 6.8% A.P. Møller - Mærsk B 6.8% Ørsted A/S 6.4% Return in the period: 31.08.2016 - 31.08.2021 William Demant Holding A/S 5.1% Coloplast B 5.0% Tryg A/S 4.8% Gn Store Nord 4.5% Pandora 4.1% *) Please note that all holdings are delayed with 1 month. Asset allocation: Sectors as of 30.07.2021, % The default for the chart is the return for the past 5 years as of end of month or, if the fund is less than 5 years old, since launch.
    [Show full text]
  • The Novozymes Report 2017
    The Novozymes Report 2017 Rethink tomorrow Contents The big picture 4 2017 in brief Accounts and performance 15 Letter from the Board of Directors 66 Performance and consolidated financial statements 18 Letter from the CEO 74 Performance and environmental data 21 Novozymes in a nutshell 76 Performance and social & governance data 78 Notes 150 Statements Our business 156 Financial statements for Novozymes A/S 26 Business model 31 Strategy 33 Risk management 38 Targets Governance 49 Corporate governance 54 Board of Directors 57 Executive Leadership Team 59 Remuneration report 63 The Novozymes stock Novozymes A/S 2 The big picture Financial highlights DKK 4% 27.9% Organic sales growth EBIT margin Sales grew by 4% organically and by 3% in DKK. EBIT margin at 27.9% was on par with last year. Sales to Food & Beverages and Bioenergy were Excluding the one-time costs relating to layoffs the most significant contributors to organic in 2017, the cost associated with the change Key figures 2017 2017 sales growth in 2017. to the Executive Leadership Team, and the loss realized outlook* relating to the Albumedix divestment, the EBIT margin was ~29% Sales growth, organic 4% 2-5% Sales growth, DKK 3% 3-6% EBIT growth 3% 3-6% EBIT margin 27.9% ~28% Net profit growth 2% 2-5% Net investments excl. 1,665 1,700- acquisitions, DKKm 1,900 Free cash flow before 2,398 2,000- acquisitions, DKKm 2,200 2% 25.6% ROIC (including goodwill) 25.6% 24-25% Net profit growth ROIC * Outlook guided as of January 18, 2017.
    [Show full text]
  • The Novozymes Report 2019
    The Novozymes Report 2019 Where we make a difference In 2019, an estimated 5.9 billion people used products made with our solutions on a weekly basis Rethink tomorrow Novozymes A/S 1 Our purpose Contents Together we find biological answers for better lives in a growing world – Let's rethink tomorrow The big picture Accounts and performance 4 2019 in brief 52 Performance and consolidated 2019 in brief 14 Five-year summary financial statements 2019 was a challenging year for 15 Letter from the Board of 60 Performance and 48% Novozymes. Several industries Directors environmental data experienced strong headwinds Novozymes holds an but there were signs of recovery in 17 Letter from the CEO 62 Performance and social estimated 48% share of Household Care. 19 This is Novozymes & governance data the global enzyme market. 21 Novozymes and the Sustainable 64 Notes Development Goals 136 Statements 142 Financial statements for Strategy Our business Novozymes A/S Novozymes’ updated strategy Better 24 Strategy 157 Glossary business with biology was launched in 29 Risk management 158 About the report June 2019. It will help us capture the right opportunities at the right time 33 Targets together with our customers. 34 Outlook for 2020 Governance 37 Corporate governance Explore 40 Board of Directors the highlights of the 42 Executive Leadership Team Novozymes Report 2019 at report2019.novozymes.com 44 Remuneration report 49 The Novozymes stock Novozymes A/S 2 4 2019 in brief 14 Five-year summary 15 Letter from the Board of Directors 17 Letter from the CEO 19 This is Novozymes 21 Novozymes and the Sustainable Development Goals Where we make a difference Novozymes’ solutions contributed to an estimated saving of 87 million tons CO 2 for our customers in 2019 The big picture Financial highlights 2019 2019 Key figures realized outlook1 DKK Sales growth, organic (1)% (2)-0% EBIT margin 28.1% 27-28% Net profit growth (2)% (5)-0% 28.1% -1% -2% Net investments excl.
    [Show full text]
  • ENGLISH JOB DENMARK Recruitment Announcements Part of the Welcome Group
    ENGLISH JOB DENMARK Recruitment Announcements Part of The Welcome Group MARKETING CREATION AND CREATE THE FUTURE: UK NATIVE SPEAKER PRODUCTION COORDINATOR, INNOVATION PROJECT BUSINESS DEVELOPMENT GN GROUP MANAGER (14327), DEMANT REPRESENTATIVES - PART TIME, If you are a born project coordinator, You will work on high-uncertainty CLERK.IO digital native and have experience technologies, ideas and concepts that have We are seeking the next generation of from the agency side, if you enjoy and the potential to significantly impact hearing ambitious sales and marketing professional excel at managing several creative and healthcare. superstars who are looking to develop their complex processes at the same time and Location: Smørum skills across technical selling, demand want to join an organization with lots of Deadline: 30 November 2020 generation, sales operations, networking opportunities to grow and develop your and negotiations. career, you should apply for this role. Contact: Thor Højlund Olsen, Location: Copenhagen Location: Ballerup Director, Discovery, [email protected] Deadline: Casting on 18 November 2020 Deadline: 23 November 2020 Contact: +45 70 55 51 00 Contact: Mette Gramkow, Team lead, +45 24 76 91 59 JAVASCRIPT TECHNICAL EVANGELIST, SITECORE RESEARCH SCIENTIST, A Technical Evangelist uses deep NOVOZYMES PEOPLE ANALYTICS LEAD, development knowledge, engaging Do you want to rethink your impact, and are HEMPEL technical writing and persuasive you passionate about application science? A newly established position as our People presentation skills to show the endless Then you might be our new agile research Analytics Lead to help us become more possibilities of creating unique experiences scientist. data-driven, and help shape improved with Sitecore.
    [Show full text]
  • Important Notice the Depository Trust Company
    Important Notice The Depository Trust Company B #: 3489-16 Date: June 20, 2016 To: All Participants Category: Dividends From: International Services Attention: Operations, Reorg & Dividend Managers, Partners & Cashiers DENMARK ADR MARKET ANNOUNCEMENT ISSUE CUSIP A.P. MOLLER - MAERSK 00202F102 CARLSBERG 142795202 CHR. HANSEN 12545M207 COLOPLAST A/S 19624Y101 Subject: DSV 26251A108 FLSMIDTH & CO A/S 343793105 GN STORE NORD 3621ME105 NOVOZYMES A/S 670108109 PANDORA 698341104 SYDBANK 87124G102 VESTAS WIND SYSTEMS A/S 925458101 Effective as of September 13, 2016 Participants can use DTC’s Corporate Actions Web (CA Web) service to certify all or a portion of their position entitled to the applicable withholding tax rate. Participants are urged to consult TaxInfo respectively before certifying their instructions over the CA Web. Important: Prior to certifying tax withholding instructions, participants are urged to read, understand and comply with the information in the Legal Conditions category found on TaxInfo on the CA Web. Questions regarding this Important Notice may be directed to GlobeTax 212-747-9100. DTCC offers enhanced access to all important notices via a Web-based subscription service. The notification system leverages RSS Newsfeeds, providing significant benefits including real-time updates and customizable delivery. To learn more and to set up your own DTCC RSS alerts, visit http://www.dtcc.com/subscription_form.php. Non-Confidential 1 DTCC Public (White) Important Legal Information: The Depository Trust Company (“DTC”) does not represent or warrant the accuracy, adequacy, timeliness, completeness or fitness for any particular purpose of the information contained in this communication, which is based in part on information obtained from third parties and not independently verified by DTC and which is provided as is.
    [Show full text]